Adarsh Raja1Rabia Asim1Muhammad Hamza Shuja2Sandesh Raja2Tazheen Saleh Muhammad1Simran Bajaj3Abdul Hadi Ansari1Hamza Ali1Iffat Ambreen Magsi1Muhammad Hammad Faridi1Hamza Ali Hasnain Sheikh1Muhammad Junaid Imran1Muhammad Ahmed1
Muhammad Sohaib Asghar4,5*- 1Department of Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan
- 2Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
- 3Department of Internal Medicine, Shaheed Mohtarma Benazir Bhutto University, Larkana, Pakistan
- 4Department of Internal Medicine, AdventHealth, Sebring, FL, United States
- 5Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States
A Corrigendum on
Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults
by Raja, A., Asim, R., Shuja, M. H., Raja, S., Muhammad, T. S., Bajaj, S., Ansari, A. H., Ali, H., Magsi, I. A., Faridi, M. H., Sheikh, H. A. H., Imran, M. J., Ahmed, M., and Asghar, M. S. (2024) Front Neurol. 15:1468961. doi: 10.3389/fneur.2024.1468961
In the published article, there was an error. Two reviewer comments inadvertently appeared in the final published article. Two sentences have been removed from the Results section, Secondary outcomes. These sentences previously stated:
Regarding change in monthly headache days, I do not see the relevance to do a sensitivity analysis. Also after excluding Ailani et al., the mean value with 95% CI does not appear so different than the previous one.
A sentence has been removed from the Results section, Meta-regression, first paragraph. This sentence previously stated:
The meta-regression is not anticipated in the statistical analysis plan. What is the purpose of such analysis?
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: atogepant, CGRP, migraine, headache, meta-analysis
Citation: Raja A, Asim R, Shuja MH, Raja S, Muhammad TS, Bajaj S, Ansari AH, Ali H, Magsi IA, Faridi MH, Sheikh HAH, Imran MJ, Ahmed M and Asghar MS (2025) Corrigendum: Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults. Front. Neurol. 16:1577914. doi: 10.3389/fneur.2025.1577914
Received: 16 February 2025; Accepted: 25 February 2025;
Published: 10 April 2025.
Edited and reviewed by: Massimiliano Valeriani, University of Rome Tor Vergata, Italy
Copyright © 2025 Raja, Asim, Shuja, Raja, Muhammad, Bajaj, Ansari, Ali, Magsi, Faridi, Sheikh, Imran, Ahmed and Asghar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Muhammad Sohaib Asghar, c29oYWliX2FzZ2hhcjEyM0B5YWhvby5jb20=